Evidence map›Paper›PMID 24597503›Full record

ArticleNano letters2014

Modular plasmonic nanocarriers for efficient and targeted delivery of cancer-therapeutic siRNA.

Xiao Huang, Alessia Pallaoro, Gary B Braun, Demosthenes P Morales, Maria O Ogunyankin, Joseph Zasadzinski, Norbert O Reich

Abstract read
In one paragraph

Article in Nano letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.IEEE transactions on nanobioscience · 2016
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiao HuangDepartment of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States.
Alessia Pallaoro
Gary B Braun
Demosthenes P Morales
Maria O Ogunyankin
Joseph Zasadzinski
Norbert O Reich
University of California, Santa Barbara · USUniversity of Minnesota · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Penetrating Peptides for Cancer TargetingR01CA152327 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2011 to 2015
$2.0M
Trans-disciplinary Postdoctoral Training in Cancer BiologyT32CA121949 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RONAI, ZEEV A. · 2007 to 2011
$1.8M
NIR Light-Activated Nanoparticles for Drug and Gene DeliveryR01EB012637 · NIBIB · UNIVERSITY OF MINNESOTA · PI ZASADZINSKI, JOSEPH ANTHONY · 2011 to 2014
$1.3M
Two-Photon Microscopy for Biomedical ResearchS10RR022585 · NCRR · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI REESE, BENJAMIN E · 2007 to 2007
$500k
NCI NIH HHS R01 CA 152327NCI NIH HHS R01 CA152327NCI NIH HHS T32 CA 121949NCI NIH HHS T32 CA121949NCRR NIH HHS S10 RR022585NCRR NIH HHS S10RR022585NIBIB NIH HHS R01 EB012637
6 · The paper itself

Abstract

We have combined a versatile and powerful route to deliver nucleic acids with peptide-based cell-specific targeting. siRNA targeting the polo-like kinase gene is in clinical trials for cancer treatment, and here we deliver this RNA selectively to cancer cells displaying the neuropilin-1 epitope using gold nanoshells. Release of the siRNA from the nanoparticles results from irradiation with a pulsed near-infrared laser, which also provides efficient endosomal escape within the cell. As a result, our approach requires 10-fold less material than standard nucleic acid transduction materials and is significantly more efficient than other particle-based methods. We also describe a particle-nucleic acid design that does not rely on modified RNA, thereby making the preparation of these materials more efficient and much less expensive. These improvements, when combined with control over when and where the siRNA is released, could provide the basis for diverse cell biological studies.

Indexed as

Gene Transfer TechniquesAmino Acid SequenceCell LineCell Line, TumorDelayed-Action PreparationsDrug Delivery SystemsEndosomesGoldHumansLasersMaleNanocapsulesNeuropilin-1PeptidesProstateProstatic NeoplasmsDelayed-Action PreparationsGoldNanocapsulesNeuropilin-1PeptidesRNA, Small Interfering

Identifiers

PMID24597503
PMCPMC3985716
OpenAlexW2332068675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.